Neimeth posts N2bn turnover, plans N5bn investment

Date:

Neimeth International Pharmaceuticals Plc has reported a turnover of N1.99bn and gross profit of N927m for the nine-month period ended June 30, 2021.

Thank you for reading this post, don't forget to subscribe!

Neimeth’s interim report showed that its operating profit stood at N198.27m while profit before and after tax stood at N84.83m each.

The company said its earnings per share closed at 4.47 kobo.

It said in a statement, “Neimeth was adjudged as the best-performing stock in the healthcare sector of the Nigerian capital market at the 2021 Nigerian Investors Value Award.

“It was the third time since 2019 that the company has won similar award based on the performance of quoted companies on the Nigerian capital market, beating other leading quoted pharmaceutical companies.”

The Managing Director, Neimeth International Pharmaceuticals, Mr Matthew Azoji, said the company had continued to show resilience, despite macroeconomic challenges, which he said had been compounded by the COVID-19 pandemic.

According to him, the company remained focused on its medium to long-term strategic plans of growing its production capacity and market share, creating enduring value for all stakeholders and combined strategy of growing market share while simultaneously creating value for shareholders.
He reaffirmed the commitment of the company to its vision of becoming a manufacturing hub for medicines and centre of excellence for pharmaceutical development in Africa.
Azoji said the company’s growth plan, which included the investment of some N5bn in capacity expansion, remained on course, adding that early gains from these strategic initiatives should be major boosts for growth in the years ahead.

Shareholders of Neimeth had recently approved a plan to inject fresh capital of N5bn to fund the construction of a pharmaceutical manufacturing facility at Amawbia, near Awka in Anambra State.

The company said the plant was designed as a multi-products plant and would be presented to the World Health Organization for certification in line with its current standards of Good Manufacturing Practice.

Upon completion and certification, the plant is expected to provide foreign and local contract manufacturing services for drug production, research and development, formulation and validation services, among others.

Naija247news
Naija247newshttps://www.naija247news.com/
Naija247news is an investigative news platform that tracks news on Nigerian Economy, Business, Politics, Financial and Africa and Global Economy.

Share post:

Subscribe

Popular

More like this
Related

Naira Appreciates Against Dollar at the NAFEM Window

March 28, 2024. Azonuchechi Chukwu. The Naira’s euphoric appreciation against the...

FG directs banks to deduct 0.375% stamp duty charges on all loans

March 28, 2024. Azonuchechi Chukwu. The Federal Government has directed commercial...

INEC disowns Anambra LP convention

28 Mar,2024 The Independent National Electoral Commission (INEC) has disowned...

NDPC investigating over 400 cases of privacy breaches Involving digital lenders

March 28, 2024. Azonuchechi Chukwu. The Nigeria Data Protection Commission (NDPC)...
Social Media Auto Publish Powered By : XYZScripts.com

Discover more from Naija247news

Subscribe now to keep reading and get access to the full archive.

Continue reading